Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-061058
Filing Date
2025-04-30
Accepted
2025-04-30 16:12:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ntla_defa14a_2025_rev.htm DEFA14A 17762
2 GRAPHIC img101534182_0.jpg GRAPHIC 1991556
3 GRAPHIC img101534182_1.jpg GRAPHIC 1585060
  Complete submission text file 0000950170-25-061058.txt   4644171
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37766 | Film No.: 25895318
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)